# Solid Biosciences Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Solid Biosciences Inc.). ## Overview Solid Biosciences Inc. is a U.S.-based biopharmaceutical company focused on developing gene therapies and related technologies for rare neuromuscular and cardiac diseases. Its pipeline includes candidates such as SGT-003, SGT-212, SGT-501, and SGT-002, supported by preclinical, clinical, manufacturing, and regulatory activities. ## Products & services • Gene therapy candidates for Duchenne muscular dystrophy • Gene therapy programs for CPVT and other cardiomyopathies • Preclinical and clinical development services for its pipeline • Manufacturing and CMC development through third-party CDMOs • Adjacent technologies such as assays and research tools - **Duchenne gene therapy programs** (40%) — Development of gene therapy candidates aimed at Duchenne muscular dystrophy. - **Cardiac gene therapy programs** (25%) — Programs targeting CPVT and other inherited cardiomyopathies. - **Preclinical and clinical development** (20%) — Discovery, laboratory testing, and clinical trial execution for pipeline candidates. - **Manufacturing and CMC support** (10%) — Third-party manufacturing, process scale-up, and drug product supply for studies. - **Adjacent technologies and assays** (5%) — Supporting technologies used to advance research and development programs. - Gene therapy candidates for Duchenne muscular dystrophy - Gene therapy programs for CPVT and other cardiomyopathies - Preclinical and clinical development services for its pipeline - Manufacturing and CMC development through third-party CDMOs - Adjacent technologies such as assays and research tools ## Customers Solid Biosciences primarily serves patients through the development of therapies for rare genetic diseases, with eventual commercialization aimed at specialty prescribers and treatment centers. In the development stage, its direct counterparties are regulators, clinical investigators, CROs, CDMOs, and potential collaboration partners rather than traditional commercial customers. Any future buyers of approved products would likely be hospitals, specialty clinics, and payers covering high-cost rare-disease therapies. - **Rare disease patients** (primary) — Patients with Duchenne muscular dystrophy, CPVT, and other inherited disorders targeted by the pipeline. - **Specialty physicians and treatment centers** (primary) — Neuromuscular and cardiac specialists who would administer or refer patients for approved therapies. - **Clinical trial ecosystem** (primary) — CROs, investigators, and trial sites that conduct preclinical and clinical studies for the company. - **Potential commercial payers** (secondary) — Insurers and health systems that would reimburse future approved gene therapies. - **Strategic collaborators** (secondary) — Licensing and collaboration partners that may fund or support development and commercialization. - Patients with Duchenne muscular dystrophy and related rare diseases - Specialty physicians and treatment centers that would prescribe approved therapies - Clinical trial sites enrolling patients in gene therapy studies - Regulators and research partners that enable development and approval - Potential commercial payers and hospital systems for future launches ## Geography Solid Biosciences is headquartered in the United States and conducts most of its development, regulatory, and corporate activities from there. Its operating model depends on a network of third-party manufacturers and research partners, which may be located outside the U.S. as programs advance. Geography matters mainly through U.S. FDA oversight, access to clinical trial sites, and supply-chain dependence on specialized manufacturing capacity. - Headquartered in the United States - Primary regulatory exposure is to the U.S. FDA - Clinical development is centered on U.S.-based programs - Manufacturing relies on third-party CDMOs, potentially global - Future commercialization would likely begin in major U.S. markets ## Strategy The company’s strategy is to advance its gene therapy pipeline through research, clinical trials, and regulatory interactions while building the manufacturing and quality infrastructure needed for later commercialization. It also seeks to expand its portfolio through additional candidates, technologies, collaborations, and in-licensing opportunities. - **Advance lead gene therapy candidates through clinical development** (short-term) — Clinical proof-of-concept is the main value driver for a pre-commercial biotech. - **Strengthen manufacturing and supply chain capabilities** (short-term) — Gene therapies require reliable cGMP manufacturing and scalable supply for trials and launch. - **Expand pipeline and technology base** (medium-term) — Broader programs can diversify scientific risk and create partnering opportunities. - **Prepare for eventual commercialization** (medium-term) — Approved gene therapies require sales, marketing, distribution, and market-access capabilities. - Advance SGT-003, SGT-212, SGT-501, and other candidates - Run clinical trials and engage with FDA and other regulators - Scale manufacturing and secure multi-source supply capability - Build commercial infrastructure for future approved products - Pursue collaborations, licensing, and pipeline expansion ## Risks Solid Biosciences faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory delays, and the possibility that its candidates never reach approval or commercialization. It also depends heavily on third-party manufacturers and external funding, so supply disruptions or capital shortfalls could materially slow development. - **Clinical development failure** [critical] — Pipeline value depends on successful trial results and acceptable safety/efficacy. - **Regulatory delay or rejection** [high] — Gene therapies require extensive FDA review and may need extra studies or holds lifted. - **Manufacturing and quality risk** [high] — The company relies on third-party manufacturers for cGMP supply and scale-up. - **Financing risk** [high] — The business expects continued losses and may need additional capital to fund operations. - **Competitive pressure** [medium] — Larger biopharma and other gene therapy developers may reach market first or with better data. - Clinical trials may fail, delay, or require additional studies - FDA or other regulators may impose holds or reject filings - Third-party CDMO quality or capacity issues could disrupt supply - Additional funding may be needed before commercialization - Competition from better-funded gene therapy developers is intense ## Accounting As a clinical-stage biotech, Solid Biosciences’ reported results are driven mainly by research and development accruals, stock-based compensation, and other judgment-heavy estimates rather than product revenue. The company also discloses derivative liabilities, which can create non-cash fair value volatility, and it relies on accruals for third-party trial and manufacturing costs that may be revised as invoices arrive. - **Accrued research and development expenses** — Can shift quarterly operating expense timing - **Equity-based compensation** — Affects reported operating loss without immediate cash outflow - **Derivative liabilities** — Can add volatility to other income/expense - **Clinical and manufacturing accruals** — Can materially affect period-to-period comparability - Accrued R&D expenses affect timing of trial and manufacturing costs - Equity-based compensation is a major non-cash expense - Derivative liabilities can create fair value gains or losses - No commercial product revenue yet, so revenue recognition is limited - Cash runway assumptions affect going-concern style disclosures --- *Last updated: 2026-04-29T04:59:22.737552+00:00*